Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/30/2013 |
| Start Date: | October 2012 |
| End Date: | March 2014 |
| Contact: | Stephen Williamson, MD |
| Email: | swilliam@kumc.edu |
| Phone: | 913-588-6029 |
The primary objective is to develop a rapid in vitro screening assay for detection of
pancreatic cancer biomarkers in blood of patients with pancreatic cancer.
The goal of the project is to develop a rapid in vitro screening assay for detection of
cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors,
based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via
protease-selective consensus (cleavage) sequences. The focus is on the quantitative
determination of active cancer-specific proteases in blood via simple fluorescence
measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and
cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore,
serve as markers for cell survival/tumor progression, angiogenesis, and tissue
remodeling/invasion
Inclusion Criteria:
Inclusion Criteria for Pancreatic Cancer Patients:
- Patients will either have a histologic diagnosis of pancreatic carcinoma or a
clinical picture consistent with pancreatic cancer and will be undergoing surgery or
a diagnostic procedure to confirm the diagnosis.
- Patients will have had no prior treatment or surgery
Inclusion Criteria for Healthy Subjects:
- Subjects will have no prior history of any cancer
Exclusion Criteria:
Exclusion Criteria for Pancreatic Cancer Patients
- Any prior treatment for pancreatic cancer
- Poorly controlled diabetes
Exclusion Criteria for Healthy Subjects
- Poorly controlled diabetes
We found this trial at
1
site
Click here to add this to my saved trials
